FDA OKs Odevixibat for Pruritus Associated With Rare Liver Disease FDA OKs Odevixibat for Pruritus Associated With Rare Liver Disease

Odevixibat (Bylvay) is the first drug approved for the treatment of severe itching in children as young as 3 months with progressive familial intrahepatic cholestasis.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news